1、2021ENVIRONMENTAL,SOCIAL&GOVERNANCE REPORTIntroductionCOVID-19 Response2|ENVIRONMENTAL,SOCIAL&GOVERNANCE REPORT 2021Healthy PeopleHealthy SocietyHealthy PlanetA Healthy AmgenAppendixCorporate Governance .55Business Ethics .56Ethical Research .58Patient Safety and Product Quality .60Cybersecurity and
2、 Data Privacy .63Government Affairs and Public Policy .65We value and welcome feedback from all stakeholders.Please send comments or questions about this report to ESGAMGEN.COMABOUT THIS REPORT This report describes our progress from January 1,2021 to December 31,2021.The content is informed by our
3、ongoing monitoring of internal and external stakeholder perspectives,direct interactions with stakeholders,a review of relevant reporting standards and frameworks,and internal analyses of the alignment of environmental,social and governance(ESG)topics with our strategy,mission and values.All of our
4、worldwide business operations are included in this report unless otherwise stated.Throughout this report,we also guide readers to additional sources of information online.We have prepared this report in alignment with the Biopharma Investor ESG Communications Guidance(the“Guidance”).Launched in 2020
5、,the Guidance identifies high-priority ESG topics for the biopharmaceutical sector and recommends how to structure information and disclosures in a useful format for investors.The Guidance integrates components and principles of the Sustainability Accounting Standards Board(SASB)Biotechnology&Pharma
6、ceuticals Sustainability Accounting Standard,as well as the Task Force on Climate-Related Financial Disclosures(TCFD)reporting standard.Our reporting also reflects our alignment with the United Nations(UN)Global Compact and Sustainable Development Goals.TABLE OF CONTENTSAbout This Report .2About Amg